Previous 10 | Next 10 |
TAMPA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference at 10:15 AM ET on Wednesday, April 19, 2023. Live audio of the virtual...
– Term Loan A Carries Significantly Lower Interest Rate – – Meaningfully Improves Debt Leverage Ratio and Reaffirms Outlook for Growth -- TAMPA, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commit...
2023-03-29 08:43:06 ET The U.S. Food and Drug Administration (FDA) accepted to review Pacira BioSciences' ( NASDAQ: PCRX ) application seeking expanded label for non-opioid pain drug Exparel. The company's supplemental new drug application (sNDA) is seeking Exparel...
TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplement...
TAMPA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that the United States Court of Appeals for the Third Circuit affirmed the District Court’s dismissal of the Company’s suit against the American Society of Anesthesiologists (...
TAMPA, Fla., March 22, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that after serving as an independent director for nine years, Yvonne Greenstreet, MBChB, ...
2023-03-16 18:45:17 ET Summary BioXcel Therapeutics, Inc. has just released results for the fourth quarter of 2022. Some analysts have expressed doubts about the commercial success of its Igalmi launch. The good growth in forms approved so far makes me very optimistic about th...
TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 9:00 AM ET on Wednesday, March 15, 2023 in Miami. Live audio of the event can be acc...
Pacira BioSciences, Inc. (PCRX) Q4 2022 Results Conference Call February 28, 2023 08:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive Officer Roy Winston - Chief Medical Officer Charlie Reinhart - Chie...
Pacira BioSciences press release ( NASDAQ: PCRX ): Q4 Non-GAAP EPS of $0.80 misses by $0.03 . Revenue of $172M (+8.0% Y/Y) misses by $1.32M . Pacira ended the fourth quarter of 2022 with cash, cash equivalents and available-for-sale investments (“cash”) o...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
2024-07-02 14:00:06 ET Oren Livnat from H.C. Wainwright issued a price target of $57.00 for PCRX on 2024-07-02 12:36:00. The adjusted price target was set to $57.00. At the time of the announcement, PCRX was trading at $21.91. The overall price target consensus is at $48...